The c-kit Mutation Analysis, Plasma-based, Leumeta® test contains 1 test with 1 biomarker.
Activating c-kit mutations have been identified in various human cancers. C-kit exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate. C-kit exon 9, 11, 13, 17 mutations have been reported in nearly 90% of GIST patients. The presence mutation usually predicts poor survival. C-kit exon 17 mutation has been reported in patients with systemic mastocytosis.